Figure 1 - uploaded by Fahad Javed
Content may be subject to copyright.
Study selection. Abbreviations: BP, blood pressure; CCB, calcium-channel blocker; DHP, dihydropyridine; NDHP, nondihydropyridine; RCT, randomized controlled trial.  

Study selection. Abbreviations: BP, blood pressure; CCB, calcium-channel blocker; DHP, dihydropyridine; NDHP, nondihydropyridine; RCT, randomized controlled trial.  

Source publication
Article
Full-text available
Background: Dual calcium-channel blocker (CCB) with a dihydropyridine (DHP) and a nondihydropyridine (NDHP) has been proposed for hypertension treatment. However, the safety and efficacy of this approach is not well known. Methods: A MEDLINE/EMBASE/CENTRAL search for randomized clinical trials published on this topic from 1966 to February 2012 w...

Context in source publication

Context 1
... total of 29 potentially eligible trials were identified, from which 6 trials satisfied the inclusion criteria and were included in this analysis (Figure 1). The trial by Bory et al. was excluded, as the doses used in the combination group were lower for both DHP and NDHP when compared with the monotherapy group. ...

Similar publications

Article
Full-text available
Background: We conducted this meta-analysis to systematically review and analyze the clinical benefits of angiotensin receptor blocker (ARB) combined with calcium channel blocker (CCB) following ineffective CCB monotherapy. Methods: PubMed was searched for articles published until August 2015. Randomized controlled trials (RCTs) evaluating the c...
Article
Full-text available
The efficacy and safety of aliskiren combination therapy with angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in patients with hypertension and cardiovascular disease remains attractive attention. We searched the Cochrane Central Register, the Clinical Trials Registry, EMBASE, MEDLINE and PubMed for relevant...

Citations

... По данным внутрисосудистого УЗИ применение амлодипина приводит к статистически значимому замедлению прогрессирования коронарного атеросклероза. Причем в группе амлодипина с исходно повышенным АД замедление прогрессирования атеросклероза было достоверным[49,50].Сравнительная оценка влияния на сердечно-сосудистую летальность антагониста АТ1-ангиотензиновых рецепторов валсартана и антагониста кальция амлодипина проведена в исследовании VALUE (Valsartan Antihypertensive Long-tern Use Evaluation)[51] с участием 15 313 больных с АГ высокого риска, которым назначали амлодипин или валсартан. В течение 5 лет у больных группы амлодипина АД снизилось несколько в большей степени, чем в группе валсартана. ...
... Alviar et al. сообщают, что подобная комбинация приводила к значительно более выраженному снижению артериального давления, нежели препараты порознь, тогда как частота побочных эффектов не изменилась. Авторы называют перспективным подобное направление, хотя и предупреждают о необходимости крупномасштабных рандомизированных исследований [13]. ...
Article
Full-text available
The paper addresses the role of calcium channel blockers (CCB) in the treatment of patients with arterial hypertension and concomitant pathology. The authors present the findings of the recent studies on CCB effects on renal function, bronchial function, and systemic inflammation. This additional information on comorbidities is essential for the doctors’ choice of optimal individualised therapy.
Chapter
Full-text available
Pyridine-based ring systems are heterocycle-structured subunits that are being abundantly employed in drug design, primarily because of their tremendous effect on pharmacological activity, which has resulted in the discovery of various broad-spectrum medicinal compounds. Pyridine derivatives are employed to treat multiple medical illnesses, including prostate cancer, AIDS, tuberculosis, angina, ulcer, arthritis, urinary tract analgesic, Alzheimer’s disease, and cardiovascular diseases. This chapter emphasized the currently available synthetic pyridine derivatives, including nimodipine, ciclopirox, efonidipine, nifedipine, milrinone, and amrinone, effects on cardiac ionic channels and their mechanisms of action for the cure. Pyridine derivatives regulate several voltage-gated ion channel behaviors, including sodium (Nav), calcium (Cav), and potassium (Kv) channels, and are set as a therapeutic approach. Particularly, calcium-channel blockers are the most common action of medicines with a dihydropyridine ring and are often used to treat hypertension and heart-related problems. Finally, this chapter gives the prospects of highly potent bioactive molecules to emphasize the advantages of using pyridine and dihydropyridine in drug design. This chapter discusses pyridine derivatives acting on cardiac ionic channels to combat CVS diseases. The book chapter describes the importance of pyridine derivatives as a novel class of medications for treating cardiovascular disorders.
Article
Background: Sodium nitroprusside is the preferred agent for the treatment of high blood pressure during acute aortic syndrome if blood pressure remains elevated after heart rate control with beta-blockers. The increasing cost of sodium nitroprusside in the USA led us to assess the efficacy and safety of intravenous clevidipine, a calcium channel blocker with quick onset of action, short half-life and significantly lower costs than sodium nitroprusside, in patients presenting with acute aortic syndrome. Methods: We performed a retrospective chart review of consecutive patients admitted to the Cleveland Clinic Cardiac Intensive Care Unit from 2013-2016 with a diagnosis of acute aortic syndrome. Patients who received intravenous sodium nitroprusside were compared with those receiving intravenous clevidipine. The primary outcome was a significant difference in blood pressure at one, three and six hours. Secondary outcomes included time to achieving blood pressure target and in hospital mortality with rates of hypotension and bradycardia as safety endpoints. Results: A total of 85 patients with suspected acute aortic pathology received clevidipine and 50 received sodium nitroprusside. Clinical and demographic characteristics were similar in both groups, except for a higher incidence of abdominal aortic aneurysm in the clevidipine group and for a trend towards higher use of labetalol in the clevidipine group. There were no significant differences in blood pressure or heart rate at one, three and six hours after starting either infusion. The rates of hypotension, bradycardia and in-hospital mortality did not differ. Time to achieve blood pressure control were also similar between groups. Conclusion: Intravenous clevidipine appears to be a safe and effective alternative to sodium nitroprusside for the management of high blood pressure during acute aortic dissection. In the USA, clevidipine could represent a cost effective therapy providing similar outcomes than sodium nitroprusside.
Article
People with diabetes often have difficulty reaching their blood pressure target, and are labelled as having resistant hypertension. Clinicians often move quickly to screen such people for secondary causes of hypertension, however such causes are rare, and resistant hypertension usually has other explanations that are significantly more common. By using a structured approach to resistant hypertension, clinicians can assist patients to reach their target blood pressure. Step 1 is to determine an out-of-office blood pressure using home or ambulatory blood pressure monitors. Step 2 is to determine the level of adherence to prescribed medications. Step 3 is to identify interfering substances. Step 4 is to check that the prescribed medications are synergistic and optimally dosed. Finally, if all other steps fail to get the patient to their blood pressure target, we consider possible secondary causes of hypertension. This approach is particularly useful in helping people with diabetes reach their blood pressure target.
Article
Introduction: Hypertension and diabetes are two of the most important modifiable risk factors for cardiovascular and renal disease. The majority of patients with diabetes also have high blood pressure (BP) and the presence of hypertension in these patients dramatically increases cardiovascular and renal risk. Areas covered: This article will discuss chemical therapies for hypertension in patients with diabetes, based on currently available evidence on the effects of antihypertensive treatment on metabolic profile and renal endpoints that are the factors mostly influencing drug choice. Expert opinion: Several lines of evidence suggest that angiotensin-converting-enzyme-inhibitors (ACEIs), angiotensin-receptor-blockers (ARBs) and calcium-channel-blockers (CCBs) have beneficial or neutral effects on carbohydrate metabolism, whereas old β-blockers and thiazide diuretics have not. Renal outcome trials clearly suggest that in proteinuric diabetic CKD ACEIs and ARBs reduce the rate of disease progression. Thus, an ACEI or an ARB, if tolerated, should be the first choice in diabetic individuals, followed by CCBs, vasodilating β-blockers and diuretics, depending on the individual patient characteristics. Recent studies suggest that the novel antidiabetic class of sodium-glucose-co-transporter 2 inhibitors may offer a small reduction in BP together with important decrease in incidence of cardiovascular and renal events in patients with type 2 diabetes.
Article
The paper addresses the role of calcium channel blockers (CCB) in the treatment of patients with arterial hypertension and concomitant pathology. The authors present the findings of the recent studies on CCB effects on renal function, bronchial function, and systemic inflammation. This additional information on comorbidities is essential for the doctors’ choice of optimal individualized therapy.